HUTCHMED Reports TAGRISSO Plus ORPATHYS Showed Clinically Meaningful Responses In Lung Cancer Patients With High MET Overexpression Or Amplification In The SAVANNAH Phase II Trial

Benzinga · 10/16 04:58
  • New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer —
  • MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies —